Sarepta Therapeutics CEO Doug Ingram to retire after tumultuous decade

Sarepta Therapeutics CEO Doug Ingram to retire after tumultuous decade

statnews.com business

Key Points:

  • Sarepta Therapeutics’ CEO Doug Ingram said Wednesday he would retire after a tumultuous decade in which he turned the biotech into a $15 billion company by pushing three different treatments for Duche

Trending Business

Trending Technology

Trending Health